- Bio2Brain Network
- ESRs
- ESR1: Particle-based formulations for the intransal transmucosal delivery of Biopharmaceuticals (IGB)
- ESR10: Understanding the relationship between chemical structure of polymeric gels and their interfacial behaviour with membranes using neutron scattering (QMUL)
- ESR11: Rational design of a panel of antibodies targeting Nogo-A (UCAM)
- ESR12: Rational design of a panel of antibodies targeting LINGO-1 (UCAM)
- ESR13: Hyaluronan based hydrogels for mucosal drug delivery (CP)
- ESR2: Bio-based hydrogels as drug delivery systems for the intranasal transmucosal delivery of Biopharmaceuticals (IGB)
- ESR3: (Bio)polymer-based particulate formulations for the intranasal transmucosal delivery of Biopharmaceuticals (MyB)
- ESR4: Analysis of mAb transport and its dependency on Fc-interacting molecules in vitro, ex vivo and in vivo (HBC)
- ESR5: Safe-by-Design (HBC)
- ESR6: Nose to Brain application of wildtype and engineered antibodies in the pathophysiological context in vivo (UNIBE)
- ESR7: Advanced imaging approaches for dissecting the mechanisms of release and trafficking of Biopharmaceuticals (LENS)
- ESR8: A computational approach to optimal design of DDS (CERTH)
- ESR9: Development of new polymeric nanogels as drug delivery systems (QMUL)
- Objectives
- Participants
- Beneficiaries
- Biberach University of Applied Sciences, Germany
- Centre for Research and Technology Hellas, Greece
- Contipro a.s., Czech Republic
- Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland
- European Laboratory for Non-Linear Spectroscopy, Italy
- Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Germany
- MyBiotech GmbH, Germany
- Queen Mary University of London, UK
- The Chancellor Masters and Scholars of the University of Cambridge, UK
- Partnerorganisations
- Beneficiaries
- ESRs
- Blog
- Contact
- Data Protection Information
- Home
- Imprint
- Newsletter unsubscribe
- Newsletter unsubscribe success
- Research
- Sitemap
